

**LISTING OF CLAIMS**

Claims 1-15 (previously canceled)

Claim 16 (previously presented): A method for inhibiting viral replication in cells susceptible to viral infection comprising contacting said cells with a leflunomide product in an amount effective to inhibit viral virion assembly.

Claim 17 (previously presented): The method of claim 16 wherein the leflunomide product is N-(4-trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide (HWA 486).

Claim 18 (previously presented): The method of claim 16 wherein the leflunomide product is N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide (A771726).

Claim 19 (previously presented): The method of claim 16 wherein the virus is a herpesvirus.

Claim 20 (previously presented): The method of claim 16 wherein the virus is selected from the group consisting of paramyxoviruses, pricornaviruses and hepatitis viruses.

Claim 21 (previously presented): The method of claim 16 wherein the virus is selected from the group consisting of CMV, HSV, measles virus, rhinoviruses, hepatitis B and hepatitis C.

Claim 22 (previously presented): The method of claim 16 further comprising contacting the cells with another anti-viral agent.

Claim 23 (previously presented): The method of claim 16 further comprising contacting the cells with a pyrimidine.

Claim 24 (previously presented): The method of claim 16 wherein the virus is resistant to anti-viral agents that inhibit viral DNA replication.

Claim 25 (previously presented): The method of claim 16 wherein cells are virally infected.